BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
The immune sequencing firm announced preliminary full-year 2019 revenues in the range of $84 million to $85 million, an increase of approximately 52 percent.
The firm will offer €4.4 billion of euro-denominated notes and $900 million in dollar-denominated notes. It will redeem another $4.5 billion in outstanding notes.
The single-cell analysis firm plans to use the proceeds to fund general corporate activities and potentially acquire businesses, products, or technologies.
Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.
The investment bank expressed doubts about Qiagen's GeneReader NGS platform, among other things, and Bruker's mixed recent record on improving its operations.
NEW YORK (GenomeWeb) – Investment banks Goldman Sachs and Leerink Partners initiated coverage of T2 Biosystems today with a Neutral and Market Perform rating, respectively, on the firm's stock.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.
